Safety of and compliance with community-based ivermectin therapy

M. Pacqué, B. Munoz, H. R. Taylor, Z. Dukuly, B. M. Greene, A. T. White

Research output: Contribution to journalArticlepeer-review

Abstract

In a study of the safety, acceptability, and efficacy of ivermectin for community-based mass treatment of onchocerciasis, the drug was issued twice, one year apart, to the population of a rubber plantation (14000 people) in Liberia, where over 80% of the adults have Onchocerca volvulusinfection. The plantation microfilarial load in a sample of adults was reduced by 86% 6 months after initial treatment and by 78% after 1 year. Compliance was 97% with each round of treatment. After the initial treatment of 7699 people, 101 (1·3%) had moderate adverse reactions. After re-treatment only 37 (0·5%) people had moderate adverse reactions. No ivermectin-related death or severe adverse reactions occurred. The data show that community-based treatment with ivermectin is well accepted and effective in reducing microfilarial loads. Ivermectin is likely to provide the first realistic means of chemotherapy-based control of onchocerciasis on a mass scale.

Original languageEnglish (US)
Pages (from-to)1377-1380
Number of pages4
JournalThe Lancet
Volume335
Issue number8702
DOIs
StatePublished - Jun 9 1990

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Safety of and compliance with community-based ivermectin therapy'. Together they form a unique fingerprint.

Cite this